Skip to main content
. 2021 May 7;80(8):1062–1069. doi: 10.1136/annrheumdis-2020-219181

Figure 3.

Figure 3

Change in MFTC and LFTC cartilage thickness up to year 5. Difference from placebo in cartilage thickness (mm) in the (A) MFTC and (B) LFTC for the mITT population (n=494). Absolute change from baseline in (C) MFTC and (D) LFTC cartilage thickness (mm) for the SAR (n=161). Means and 95% CIs shown. *p<0.05, **p<0.005, ***p<0.001. BL, baseline; LFTC, lateral femorotibial compartment; MFTC, medial femorotibial compartment; mITT, modified intention to treat; q6mo, every 6 months; q12mo, every 12 months; SAR, subgroup at risk; TFTJ, total femorotibial joint.